A medical cannabis company called Tilray has launched a new clinical trial to investigate the use of cannabis to treat autism spectrum disorder (ASD). The trial is being conducted in collaboration with the University of California, San Diego.

The trial is enrolling children and adolescents with ASD who are experiencing severe symptoms, such as irritability, aggression, and repetitive behaviors. The participants will be randomized to receive either a cannabis-based treatment or a placebo. The cannabis-based treatment will contain cannabidiol (CBD), a non-psychoactive compound in cannabis that has been shown to have anti-anxiety and anti-inflammatory effects.

The trial will last for 12 weeks, and the researchers will assess the participants’ ASD symptoms, sleep quality, and overall quality of life at the start of the study, at the end of the 12-week treatment period, and at 6-month and 12-month follow-up visits.

The results of this clinical trial could be significant. ASD is a complex condition with no known cure, and there is a great need for new and effective treatments. If the trial finds that cannabis-based treatments are safe and effective for ASD, it could lead to new treatment options for children and adolescents with this condition.

This is the latest in a growing number of clinical trials investigating the use of cannabis to treat ASD. Other trials are evaluating the use of cannabis to improve social communication skills, reduce anxiety, and improve sleep quality in children with ASD.

The results of these clinical trials will help to shed light on the potential benefits and risks of using cannabis to treat ASD.

https://images.squarespace-cdn.com/content/v1/5488a9e6e4b0563d5788db1a/ec91550b-8b07-4a08-ab74-8465a4676b41/TilrayBrands_Logo_White_RBG_Horiz-01.png?format=1500w

Tilray, a medical cannabis company, has launched a clinical trial in collaboration with the University of California, San Diego to investigate the use of cannabis to treat autism spectrum disorder (ASD) ¹. The trial is enrolling children and adolescents with ASD who are experiencing severe symptoms, such as irritability, aggression, and repetitive behaviors. The participants will be randomized to receive either a cannabis-based treatment or a placebo. The cannabis-based treatment will contain cannabidiol (CBD), a non-psychoactive compound in cannabis that has been shown to have anti-anxiety and anti-inflammatory effects¹.

The trial will last for 12 weeks, and the researchers will assess the participants’ ASD symptoms, sleep quality, and overall quality of life at the start of the study, at the end of the 12-week treatment period, and at 6-month and 12-month follow-up visits¹.

ASD is a complex condition with no known cure, and there is a great need for new and effective treatments. If the trial finds that cannabis-based treatments are safe and effective for ASD, it could lead to new treatment options for children and adolescents with this condition¹.

This is the latest in a growing number of clinical trials investigating the use of cannabis to treat ASD. Other trials are evaluating the use of cannabis to improve social communication skills, reduce anxiety, and improve sleep quality in children with ASD¹²³.

The results of these clinical trials will help to shed light on the potential benefits and risks of using cannabis to treat ASD.

Learn more:

1. molecularautism.biomedcentral.com2. cannamd.com3. asatonline.org4. cnn.com5. clinicaltrials.gov